Optimizing Freeze Thaw Processes for Cell and Gene Therapy Commercialization

recorded webinar

Numerous cell and gene therapy workflows rely on the ability of the process to be halted and re-established via freezing and thawing of intermediate and final product formulations. Early process and tool decisions can help overcome future complexity and uncertainty. See how to address freeze/thaw manufacturing capacity and infrastructure challenges by working in partnership with a well-resourced freeze/thaw ecosystem center.

Join Ross Acucena | Applications Director, Life Sciences in this webcast learn about:

  • Facilities and infrastructure to design and deploy optimized freeze thaw workflows

  • Single-use systems protect the integrity, efficacy, and purity of your product

  • Capabilities to support your achieving critical clinical development and commercialization objectives.

Key Learning Objectives

  • Understand process and tool decisions that help overcome future complexity and uncertainty

  • See how to address freeze/thaw manufacturing capacity and infrastructure challenges

  • Discover working in partnership with a well-resourced freeze/thaw ecosystem center


About the Presenter:

Ross Acucena | Applications Director, Life Sciences

ross-acucena-webinar-thumbnail-1Mr. Acucena has 20 years of experience in pharma and biopharma working early in his career as a process engineer and manufacturing leader for pharma and biopharma operations. The last 14 years having been spent in the supplier space working in various capacities in technical marketing, regulatory consulting, product development, and business leadership at MilliporeSigma, GE Biopharma, and currently with Entegris. Ross’ technical work has focused primarily on filtration applications and the successful implementation of single-use technology across many bioprocess unit operations. He holds a B.S. degree in chemical engineering and MBA both from UMASS Lowell.